Open AccessA new immunosuppressant, FTY720, in canine kidney transplantation: effect of single‐drug, induction and combination treatments
Author(s) -
Suzuki Tomomi,
Jin Maeng Bong,
Shimamura Tsuyoshi,
Yamashita Kenichiro,
Taniguchi Masahiko,
Nomura Masaru,
Yokota Ryouichi,
Fukai Moto,
Magata Shinichiro,
Horiuchi Hiroyuki,
Fujita Miri,
Nagashima Kazuro,
Furukawa Hiroyuki,
Todo Satoru
Publication year - 2004
Publication title -
transplant international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.998
H-Index - 82
eISSN - 1432-2277
pISSN - 0934-0874
DOI - 10.1111/j.1432-2277.2004.tb00389.x
Subject(s) - medicine , tacrolimus , immunosuppression , pharmacology , transplantation , pharmacokinetics , drug , kidney transplantation , kidney , adverse effect , ciclosporin , nephrology , urology
Three different types of treatment were conducted to clarify the properties of a novel immunomodulator, FTY720, in canine kidney allograft models. Survival, biochemical and hematological tests, pharmacokinetics, and histopathology of grafts and extra‐renal organs were analyzed. Accompanying a remarkable reduction in circulating lymphocytes, single‐drug treatment of FTY720, ranging from 0.05 to 10 mg/kg, exhibited significant prolongation of graft survival without a dose‐dependent effect. Short‐course induction with FTY720 at 5 mg/kg per day exhibited similar anti‐rejection effects as did single‐drug treatment but no advantage in rescuing ongoing rejection. In combination with cyclosporine (CsA; 5 mg/kg) or tacrolimus (FK; 0.5 mg/kg), FTY720 had an additive effect. Trough blood concentrations of FTY720 were linearly correlated with dose. No animal showed critical adverse effects at any point. FTY720 holds promise as a candidate in a new category of drugs that can be combined with conventional agents for induction and maintenance immunosuppression in clinical organ transplantation.